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Abstract: Around three million patients die due to airway inflammatory diseases each year. The most
notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore,
new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they
regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated,
and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD.
The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway
inflammation show promising results, but several challenges still need to be overcome. One such
challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards
specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to
validate HDACs further as targets for new anti-inflammatory pulmonary treatments.
Keywords: asthma; COPD; inflammation; NF-κB; HDAC; acetylation; post translational modification
(PTM); inhibitor; drug design; co-repressor complex; review
1. Introduction
Inflammatory pulmonary diseases are among the most common health problems worldwide.
Currently, approximately 339 million people suffer from asthma, which results in 250 thousand
preventable deaths annually [1,2]. Similar numbers have been reported for Chronic Obstructive
Pulmonary Disease (COPD). About 384 million people were estimated to have COPD and 3 million
people died because of it in 2010 [3–6]. COPD is a slow and inevitably progressing disease that, most
notably in the later stages, is very debilitating [7]. Inflammatory pulmonary diseases, such as asthma
and COPD, are generally chronic and can severely reduce the quality of life. However, to date, there is
only a limited number of effective therapeutics available for these diseases. From this perspective,
novel molecular mechanisms that can be targeted by novel therapeutics need to be identified in order
to allow for the development of more sophisticated treatment strategies [1–4,8].
Inflammation in asthma and COPD is mediated by multiple regulatory mechanisms. On the
molecular level, cellular signaling in inflammation is critically regulated by post-translational
modifications (PTMs). The dynamic process of addition or removal of PTMs by respective enzymes
influences the properties of the involved protein. The most well-studied PTM is acetylation, in which
an acetyl-group is added to a lysine residue by a histone acetyl transferase (HAT) or removed by a
histone deacetylase (HDAC). As an important example, acetylation of histones facilitates transcriptional
activation either by neutralizing the ionic interaction between DNA and the histones or by forming
a binding site for chromatin remodeling proteins and transcription factors [9,10]. Disruption of this
process results in abnormal gene expression that contributes to the pathogenesis of asthma and COPD.
Restoration of protein acetylation thus offers an interesting avenue in the search for new treatments for
asthma and COPD.
In this review, we aim to describe the molecular mechanisms in asthma and COPD, wherein
protein acetylation plays a key role. Based on these mechanisms, we aim to define the potential utility
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of histone deacetylase inhibitors (HDACi) as therapeutics in inflammatory pulmonary diseases and
summarize the recent development of isoform selective inhibitors. Lastly, we intend to complement
recent reviews covering developments in targeting HDAC complexes with small molecule inhibitors
and analyze which complexes are important for inflammation. An important future challenge will be
to develop tools that selectively interfere with HDAC complexes involved in inflammation.
2. Pathogenesis of Asthma
2.1. Cellular Mechanisms of Asthma
Asthma is a multifactorial disease with a clear inflammatory component [11]. The
pathophysiological mechanisms of inflammation in asthma can broadly be divided into T-helper 2-high
(type 2) and T-helper 2-low (non-type 2) subtypes [12]. Hallmarks of T-helper 2-driven inflammation
are the presence of the cytokines IL-4, IL-5 and IL-13 and the involvement of mast cells, eosinophils
and IgE-producing B cells [13]. These cells influence each other with the mentioned cytokines to
mount an inflammatory response. For example, IgE-dependent activation of mast cells triggers
them to release their granules containing histamine and tryptase and to generate pro-inflammatory
cytokines such as prostaglandin D2, cysteinyl leukotrienes (LTC4 and LTD4) and adenosine [14,15].
Mast cells are also key sources of the allergy associated cytokines IL-4 and IL-5 [16]. IL-4 aggravates
CD4+ T cells to differentiate into T-helper type 2 cells and further enhances IgE-mediated immune
responses and inflammatory cell recruitment [17,18] and IL-5 induces generation of novel eosinophils
in the bone marrow and their subsequent chemotaxis towards inflamed lung tissue leading to airway
eosinophilia [19]. Eosinophils are the key effector cells that cause most of the tissue damage through
release of proteases; Figure 1. Distinctively, where type 2 inflammation can be suppressed by inhalation
of corticosteroids, non-type 2 inflammation is largely unresponsive to corticosteroid therapy [20].
The molecular and cellular mechanisms that underpin non-type 2 inflammation in asthma are less
clear, but may principally involve neutrophils and high levels of IL-17 instead of eosinophils and IL-4,
IL-5 and IL-13 [20,21]. Airway neutrophilia in non-type 2 asthma is the result of an extended lifespan or
failed clearance of apoptotic neutrophils and has mostly been observed in severe cases of asthma [22].
As a plausible pathological mechanism, neutrophils form neutrophil extracellular traps (NETs) that may
damage nearby lung tissue and impede the resolution of inflammation; Figure 1 [23,24]. NET formation
starts with disassembly of the nuclear envelope, followed by DNA decondensation and rupture of
the plasma membrane to expel web-like structures of DNA decorated with histones, proteases and
peroxidases [25]. Such NET formation, or NETosis, kills the neutrophil. Additionally, neutrophils
are known to degranulate and eject DNA to create NETs extracellularly and leave an anucleated cell
body, called a cytoplast, behind [26]. Cytoplasts activate lung dendritic cells to promote differentiation
of CD4+ T cells into T-helper 17 cells, which express IL-17 [26]. IL-17 stimulates epithelial cells to
produce IL-8 [27] and thus leads to an increase in the production and recruitment of neutrophils,
thereby creating a vicious cycle of neutrophil induced lung damage.
Regardless of the type of inflammation, asthma is further pathologically characterized by abnormal
structural changes in the airway epithelium and submucosa that lead to airway obstruction, airway
hyperresponsiveness and airway mucosal inflammation [28,29]. The most apparent change in the
epithelium is goblet cell hyperplasia [30]. Changes in the submucosa include smooth muscle cell
hyperplasia and subepithelial fibrosis [28]. Whether airway remodeling is driven or just modified by
inflammation is unclear, but it is clear that inflammation increases the susceptibility to exacerbation
of the disease. Therefore, attenuating the persistent expression of inflammatory molecules required
for the recruitment and activation of neutrophils, eosinophils and T lymphocytes offers a way to
control asthma.
Epigenomes 2019, 3, 19 3 of 25
Epigenomes 2019, 3, x FOR PEER REVIEW 3 of 25 
 
 
Figure 1. Key cellular mechanisms in asthma and COPD. In asthma, allergen exposure results in 
airway remodeling through a persistent type-2 inflammatory response. This response increases 
eosinophils and damages lung tissue by released proteases from granules (orange dots). Eosinophilic 
asthma can be suppressed with corticosteroid therapy. In COPD, cigarette smoke results in chronic 
bronchitis and emphysema through a persistent non-type 2 inflammatory response. This response 
increases neutrophils and damages lung tissue by released proteases from granules (orange dots) and 
DNA in neutrophil extracellular traps (NETs). Corticosteroid treatment is largely ineffective in 
suppressing neutrophilic inflammation [23,24]. 
2.2. Role of HDACs in Asthma 
The acetylation status of proteins in asthma is reported to be maintained by an intricate balance 
of HATs and HDACs. There are four main classes of HDACs. The class III HDACs use nicotinamide 
adenine dinucleotide (NAD+) as cofactor. These HDACs are named sirtuins and can reside in the 
nucleus, mitochondria or cytoplasm, depending on the isoform [31]. Class I, II and IV HDACs depend 
on a zinc ion in their active site for catalytic activity [32,33]. Class I HDACs, HDAC1, 2, 3 and 8 are 
generally localized in the nucleus. Class IIA HDACs include HDAC4, 5, 7, 9 and class IIB harbors 
HDAC6 and 10 and have mostly cytoplasmic functions [34,35]. Class IV comprises the elusive 
HDAC11, which is only found in immune cells [36]. The family of proteins that has HAT activity is 
even more diverse. 
HAT activity and the acetylation state of histones is increased in biopsies from children and 
adults suffering from asthma [37,38]. Acetylation of histone 3 lysine 27 (H3K27ac) and mono-
methylation of H3K4 are essential in maturation of progenitor CD4+ cells into T-helper 2 cells and 
thus for the pathophysiology of asthma [39]. Additionally, a study found a small decrease in the 
expression of HDAC1 and HDAC2 in bronchial biopsies of asthma patients compared with healthy 
individuals [38]. Alveolar macrophages from asthmatic patients are also found to harbor a decreased 
deacetylase activity related to a decreased expression of HDAC1. The same decrease was not found 
in circulating blood monocytes thus confirming the notion that aberrant HDAC expression is 
i re 1. ey cellular mechanisms in asthma and COPD. In asthma, allergen exposure results in airway
remodeling through a persistent type-2 inflammatory response. This response increases eosinophils
and damages lung tissue by released proteases from granules (orange dots). Eosinophilic asthma can
be suppressed with corticosteroid therapy. In COPD, cigarette smoke results in chronic bronchitis
and emphysema through a persistent non-type 2 inflammatory response. This response increases
neutrophils and damages lung tissue by released proteases from granules (orange dots) and DNA in
neutrophil extracellular traps (NETs). Corticosteroid treatment is largely ineffective in suppressing
neutrophilic inflammation [23,24].
2.2. Role of HDACs in Asthma
The acetylation status of proteins in asthma is reported to be maintained by an intricate balance of
HATs and HDACs. There are four main classes of HDACs. The class III HDACs use nicotinamide
adenine dinucleotide (NAD+) as cofactor. These HDACs are named sirtuins and can reside in the
nucleus, mitochondria or cytoplasm, depending on the isoform [31]. Class I, II and IV HDACs
depend on a zinc ion in their active site for catalytic activity [32,33]. Class I HDACs, HDAC1, 2, 3
and 8 are generally localized in the nucleus. Class IIA HDACs include HDAC4, 5, 7, 9 and class IIB
harbors HDAC6 and 10 and have mostly cytoplasmic functions [34,35]. Class IV comprises the elusive
HDAC11, which is only found in immune cells [36]. The family of proteins that has HAT activity is
even more diverse.
HAT activity and the acetylation state of histones is increased in biopsies from children and adults
suffering from asthma [37,38]. Acetylation of histone 3 lysine 27 (H3K27ac) and mono-methylation
of H3K4 are essential in maturation of progenitor CD4+ cells into T-helper 2 cells and thus for the
pathophysiology of asthma [39]. Additionally, a study found a small decrease in the expression of
HDAC1 and HDAC2 in bronchial biopsies of asthma patients compared with healthy individuals [38].
Alveolar macrophages from asthmatic patients are also found to harbor a decreased deacetylase
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activity related to a decreased expression of HDAC1. The same decrease was not found in circulating
blood monocytes thus confirming the notion that aberrant HDAC expression is localized at the site
of inflammation [40]. The decreased expression of HDAC1 is also proposed to be a biomarker for
severe asthma [41]. The extent of HDAC1 reduction is speculative, since a slight increase in HDAC1 in
patients suffering from severe asthma compared with regular patients has also been observed [42].
The expression levels of other HDACs has so far not been adequately characterized. In summary,
the expression of HDAC1 and HDAC2 in asthma is either slightly increased or decreased, and HAT
activity is slightly increased.
In addition to differential HDAC expression, single nucleotide polymorphisms in both HDAC1
and HDAC2 have been observed in patients with asthma [43]. A polymorphism in HDAC1 was shown
to have a significant relationship with asthma severity and its presence was associated with lung
function improvements in response to inhaled corticosteroid treatment in childhood asthmatics [43].
However, the functional role of the polymorphism was not elucidated.
3. Pathogenesis of COPD
3.1. Cellular Mechanisms of COPD
Increased oxidative stress as a result of the inhalation of noxious particles, particularly those
derived from cigarette smoke, is a key driving mechanism in the pathogenesis of COPD and leads
to the destruction of lung parenchyma [44]. This process is mediated by cytotoxic CD8+ T cells,
macrophages and neutrophils. These cells release various proteases, such as elastase and matrix
metalloproteinase 9 and 12, that break down connective tissue in the lung parenchyma to result in
emphysema [45]. The proteases, together with epidermal growth factors, also induce goblet cell
hyperplasia and enhance mucus production and secretion to result in chronic bronchitis [46]. The
release of proteases by neutrophils in COPD is, similar to non-type 2 inflammation in asthma, in part
the result of NET formation, see Figure 1, mediated by IL-8 [23,24]. In addition to elucidation of the
cellular mechanisms, research in COPD has focused at unravelling the intra-cellular pathways that
are activated in the inflammatory cells in COPD. In particular, the mechanism behind corticosteroid
insensitivity and strategies to revert it have gained attention. These strategies converge at restoring
HDAC2 activity, as will be discussed in the next paragraph.
3.2. Role of HDACs in COPD
Patients suffering from severe COPD are found to express less than 5% of the HDAC2 that
nonsmokers do [47]. This decreased expression of HDAC2, which deacetylates histone 4 (H4) at
the IL-8 promotor, correlates with disease progression and is proposed as biomarker for disease
severity [48,49]. Additionally, HDAC5 and 8 were expressed to a lesser extent, SIRT1 activity is
decreased, HDAC1, 3, 4, 6 and 7 expression levels were unchanged and the expression and activity
of HDAC9, 10, 11 and the other sirtuins is unknown [49,50]. Altogether, these studies indicate that
HDAC expression and activity is altered in COPD.
Whether the observed decrease in HDAC2 expression in COPD is truly part of the etiology of
the disease is difficult to assess. A study that exposed rats to cigarette smoke found a decrease in the
expression of HDAC2 after 3 days but not after 8 weeks of cigarette exposure [51]. The initial decrease
after 3 days can be the result of a cascade of reactions originating from oxidative stress. Oxidative stress
is mediated by a combination of superoxide anions and nitric oxide, derived from cigarettes smoke,
to provide peroxynitre [52,53]. The formed peroxynitre is anticipated to nitrate tyrosine residues
on HDAC2 [53]. These nitrated residues then trigger ubiquitination and subsequent proteasomal
degradation of HDAC2 [54]. Furthermore, reactive oxygen species activate phosphoinositide-3-kinases,
the class I PI3K-δ isoform in particular. The downstream kinase AKT, or PI3K-δ itself, phosphorylates
the serine residues on HDAC2, also leading to ubiquitination and proteasomal degradation [55]. This is
an explanation for the initial decrease in HDAC2 after 3 days. In the weeks after the initial decrease in
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HDAC2, synthesis of HDAC2 is upregulated to counteract the proteasomal degradation and to return
HDAC2 levels to those found pre-smoke exposure. This would mean that the observed long-term
reduction in HDAC2 expression in COPD patients has a different origin.
The group led by Barnes identified HDAC2 as an important regulator of the glucocorticoid
receptor (GR) pathway. The GR receptor moves to the nucleus upon activation by a glucocorticoid.
There the GR is deacetylated by HDAC2, which allows the GR to form a protein–protein complex
that represses the NF-κB pathway [56–58]. This attenuates inflammation in asthma patients taking
corticosteroid medication [59]. Conversely, a decrease in the expression of HDAC2, through activation
of PI3K-δ during oxidative stress, abolishes the effect of glucocorticoids in patients with COPD [60].
The GR is then not deacetylated and thus cannot repress NF-κB. As further proof, restoration of HDAC2
activity by inhibition of PI3K-δ by either nortryptiline or a low-dose of theophylline helps to alleviate
glucocorticoid irresponsiveness in COPD [61–63].
Interestingly, glucocorticoid irresponsiveness might also result from the upregulation of the β
isoform of the GR. Upon treatment with glucocorticoids, transcription of the GRβ isoform is upregulated,
especially in the case of concomitant exposure to IL-17, which is increased in COPD [64–67]. GRβdirectly
interferes with the promotor activity of HDAC2 to result in a decreased expression of HDAC2 [68].
In this way, the observed reduced level of HDAC2 expression is mainly the result of glucocorticoid
treatment, in combination with an increased level of IL17, and not a direct effect of inhalation of noxious
particles. This would constitute an acquired form of resistance towards glucocorticoids. The previously
mentioned HDAC expression data in COPD patients taking glucocorticoids was not corrected for the
potentially confounding variable of glucocorticoid treatment.
Altogether, the group led by Barnes identified HDAC2 as an important player in activating the
anti-inflammatory response upon activation of the GR pathway with glucocorticoids. Additionally,
inhalation of noxious particles is linked to an acute decrease in the levels of HDAC2 and these lower
levels of HDAC2 might be maintained by continuous smoke exposure and glucocorticoid treatment.
4. The Role of NF-κB Acetylation in Asthma and COPD
The NF-κB signaling pathway plays a central but complex role in asthma and COPD and in
inflammation in general. The pathway converges on NF-κB and related transcription factors, which
bind to the promotors of pro-inflammatory genes and increase their expression. Importantly, the
activity of the NF-κB protein complex is influenced by acetylation. NF-κB contains seven lysine
residues that can all undergo the process of acetylation and deacetylation in a site-specific manner. The
CBP/p300 acetyltransferases play a major role in acetylating the seven lysine residues on NF-κB [69].
Although HDAC1 and HDAC2 are known to interact with NF-κB, deacetylation of the lysine residues
is mostly under the control of HDAC3 [70]. To be more precise, HDAC3 deacetylates lysine 122, 123,
314 and 315, which in their acetylated form negatively regulate NF-κB activity [71]. This is further
supported by the finding that HDAC3-deficient macrophages induce only half of the genes linked to
LPS-induced inflammatory gene expression [72].
Acetylation of lysines 122 and 123 inhibits binding towards DNA [70]. On the other hand,
acetylation of lysines 218 and 221 on subunit p65 (RelA) prevents interaction with the inhibitory protein
IκBα, allowing translocation towards the nucleus [73]. Additionally, lysine 310 acetylation is needed
for full transcriptional activity of p65, possibly by being a binding site for bromodomain containing
proteins that direct transcription [73,74]. Intriguingly, acetylation of lysines 314 and 315 direct NF-κB
towards specific promoter regions [75]. As an example of how acetylation controls the binding site of
NF-κB in asthma, the bromodomain protein BRD4 has a binding site for the acetylated NF-κB subunit
p65 as well as a binding site for acetylated histones H3k9 and H3k27. In this way, BRD4 directs the
transcription factor to specific locations along the chromatin to increase the transcription of genes
related to proliferation and inflammation [76]. This means that the transcriptional activity of NF-κB
depends on acetylation. More importantly, the affinity towards different promoters and interaction
with transcriptional proteins changes upon acetylation of NF-κB.
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5. HDACi in Asthma and COPD
Currently over 100 HDACi are in clinical trials for cancer therapy [77] and various reports
suggest that HDACi could also be effectively used to modulate inflammatory diseases, in part
because the underlying disease mechanics in cancer overlap with inflammation [78,79]. Moreover, the
anti-inflammatory effects of HDACi are seen at concentrations 10–100-fold lower than their cell-killing
properties observed in cancer [80]. Hence, using HDACi for the treatment of inflammatory diseases,
like asthma and COPD, is a topic of current research.
Given that HDAC3 is a positive regulator of NF-κB mediated inflammation, inhibitors of
HDAC3 have been proposed as novel therapeutics to combat inflammation in COPD and asthma [5].
In support of this, selective inhibition of HDAC3 with the inhibitor RGFP966 in LPS/IFN-γ stimulated
macrophages attenuated the NF-kB transcriptional activity and demonstrated anti-inflammatory
effects [81]. However, the acetylation status of NF-κB p65, histone H3 and histone H4 was unaffected,
and the most promising effects were seen at a relatively high concentration of 10 µM, at which RGFP966
also inhibits HDAC1 and HDAC2. On the other hand, siRNA-mediated downregulation of HDAC3
reduced the expression of the pro-inflammatory genes IL-1β, IL-6 and IL-12b up to 60%. This may point
to an important structural role for HDAC3 in inflammation instead of its catalytic role in deacetylation.
Whether selective pharmacological inhibition of HDAC3 in in vivo models of asthma or COPD will be
beneficial remains to be seen. Knocking-out HDAC3 might be a more promising approach.
Nonetheless, inhibition of HDAC1, 2 and 3 by entinostat (Figure 2A) in LPS/IFN-γ induced
macrophages in a COPD mouse model led to increased acetylation of NF-κB, increased translocation
towards the anti-inflammatory IL-10 promoter and subsequent increased expression of IL-10 [82].
Inhibition of HDAC1, 2 and 3 furthermore reduced inflammation through decreased pro-inflammatory
cytokine expression of IL-8, IL-6 and IL-1β (Table 1). In conclusion, entinostat clearly reduced cigarette
smoke-induced airway inflammation in mice and therefore shows potential for the treatment of COPD.
In addition to HDAC1/2/3, HDAC6 and HDAC8 are important in the regulation of cellular
processes in inflammation. For example, HDAC8 is known to deacetylate cortactin. This promotes
actin filament polymerization and subsequent smooth muscle contraction, which plays an important
role in airway inflammation and remodeling [83]. Selective inhibition of HDAC8 with the inhibitor
PCI-34051 (Figure 2B) has been shown to attenuate airway hyperresponsiveness and inflammation
and counteract airway remodeling to a certain extent [84]. Another HDAC that is important in airway
remodeling is HDAC6, which primary function is the deacetylation of α-tubulin. Tubulin is a major
component of the cytoskeleton and is thereby involved in cell motility [85,86]. Acetylation of α-tubulin
leads to stabilized microtubules, and thereby decreases cellular motility. The importance of HDAC6 is
exemplified by knock-out mouse models that display impeded macrophage migration and motility [87].
Fibroblasts also have reduced motility upon inhibition of HDAC6 [87,88]. Inhibiting HDAC6 could in
this way attenuate airway remodeling in inflammation. Indeed, upon treatment of asthmatic mice with
the HDAC6 selective inhibitor tubastatin A (Figure 2C), airway hyperresponsiveness and inflammation
were mitigated along with a decrease in airway remodeling markers [84]. Additionally, mice that were
exposed to cigarette smoke and injected with tubastatin A were protected from cigarette smoke-induced
mucociliary clearance disruption [89]. To summarize, HDAC6 and HDAC8 could be targeted with
selective HDACi to combat airway remodeling and inflammation in both asthma and COPD.
More general inhibition of multiple HDACs in in vivo models of airway inflammation also point
towards a beneficial anti-inflammatory effect. The non-selective HDACi TSA (Figure 2D) reduces
inflammation in human precision cut lung slices and in in vivo mouse models [90,91]. TSA treatment
reduced inflammation by reducing the expression of IL-17 and T-helper 17 cell numbers, while
increasing Treg cell activation. Furthermore, the expression of TGF-β in the bronchoalveolar lavage
fluid increased following HDAC inhibition in a mouse model of asthma [84]. These changes were
associated with increased acetylation at the TGF-β promoter.
The anti-inflammatory effects of TSA have also been postulated to be partly the result of
enhanced apoptosis in neutrophils and eosinophils through activation of the c-jun-N-terminal kinase
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pathway involving caspases 3 and 6 [92]. TSA was shown to have an additive effect on apoptosis
in eosinophils following glucocorticoid treatment and TSA antagonized glucocorticoid-induced
neutrophil survival [92]. Similar effects have been observed for other non-selective HDACi, which
dose-dependently switch neutrophil death from NETosis to apoptosis [93]. This could have important
implications for the timely execution of neutrophil apoptosis which has been reported to be dysregulated
in severe asthma [22]. Yet, non-selective HDACi also induce apoptosis in macrophages by decreasing
the expression of the anti-apoptotic Bcl-2–like protein Bfl-1 in macrophages [94]. Macrophages play an
important role in the removal of apoptotic cells [95]. Increased apoptosis of eosinophils and neutrophils
without their timely clearance by macrophages will result in disintegration of the apoptotic cells,
causing damage to lung tissue and propagation of the inflammatory response [96]. Yet, in addition
to macrophages, airway epithelial cells are also capable of phagocytosing apoptotic eosinophils [97]
and these epithelial cells, like many other cell-types, do not undergo apoptosis following HDACi
treatment [98].
In conclusion, both isoform selective inhibition, as well as more general inhibition of HDACs,
seem to offer treatment options in asthma and COPD (Table 1). Current investigations aim at defining
the importance of specific HDAC isoforms in terms of their structural role or their catalytic role. This
provides potential novel starting points for drug discovery. Inhibition of the catalytic activity of
HDAC6 and HDAC8 could potentially alleviate airway remodeling and decrease inflammatory cell
motility. In contrast, complete knock-out of HDAC3, as described in the beginning of this paragraph,
might be required to attenuate airway inflammation.
Table 1. Effects of histone deacetylase inhibitors in in vivo models of asthma and COPD. The plus
sign (+) indicates inhibition and the minus sign (−) indicates no inhibition of the respective histone








Tubastatin A − − − + − Reduced inflammation











exposed mice [82] Entinostat + + + − −
Reduced expression of IL-8 and
decreased influx of neutrophils
Cigarette smoke




Epigenomes 2019, 3, x FOR PEER REVIEW 7 of 25 
 
neutrophil survival [92]. Similar effects have been observed for other non-selective HDACi, which 
dose-dependently switch neutrophil death from NETosis to apoptosis [93]. This could have 
important implications for the timely executi n of neutrophil apoptosis which has been reported to 
be dysregulated in severe asthma [22]. Yet, non-selective HDACi also induce apoptosis in 
macrophages by decreasing the expression of the anti-apoptotic Bcl-2–like protein Bfl-1 in 
macrophages [94]. Macrophages play an important role in the removal of apoptotic cells [95]. 
Increased apoptosis of eosinophils and neutrophils without their ti ely clearance by macrophages 
will result in disintegration of the apoptotic cells, causing damage to lung issue and propagation of 
the inflammatory response [96]. Yet, in addition to macrophages, airway epithelial cells are also 
capable of phagocytosing apoptotic eosinophils [97] and these epithelial cells, like many other cell-
types, do not undergo apoptosis following HDACi treatment [98]. 
In conclusion, both isoform selective inhibition, as well as more general inhibition of HDACs, 
seem to offer treatment options in asthma and COPD (Table 1). Current investigatio s aim at defining 
the importance of specific HDAC isoforms in terms of their structural role or their catalytic role. This 
provides potential novel starting points for drug discovery. Inhibition of the catalytic activity of 
HDAC6 and HDAC8 could potentially alleviate airway remodeling and decrease inflammatory cell 
motility. In contrast, complete knock-out of HDAC3, as described in the beginning of this paragraph, 
might be required to attenuate airway inflammation. 
Table 1. Effects of histone deacetylase inhibitors in in vivo models of asthma and COPD. The plus 
sign (+) indicates inhibition and the minus sign (−) indicat s no inhibition of the respective histone 
deacetylase isoforms at relevant concentrations. 
In vivo Model 
Histone Deacetylase 
Effect 
Inhibitor 1 2 3 6 8 
Asthma 
Chronic asthmatic 
mouse model [84] 
Tubastatin A − − − + − Reduced inflammation 
PCI-34051 − − − − + Reduced hyperresponsiveness 
and inflammation 
Murine n ate allergic 
lung inflammation 
[90] 
Trichostatin A + + + + + 
Decreased amount of 







exposed mice [82] 
Entinostat + + + − − Reduced expression of IL-8 and 
decreased influx of neutrophils 
Cigarette smoke 
exposed mice [89] 
Tubastatin A − − − + − 
Protection from cigarette-
smoke induced mucociliary 
clearance disruption 
 
Figure 2. Histone deacetylase inhibitors used in in vivo models of asthma or chronic obstructive 
pulmonary disease. (a) Structure of the HDAC1/2/3 selective inhibitor entinostat. (b) Structure of the 
HDAC6 selective inhibitor tubastatin A. (c) Structure of the HDAC8 selective inhibitor PCI-34051. (d) 
Structure of the non-selective HDAC inhibitor trichostatin A. 
Figure 2. Histone deacetylase inhibitors used in in vivo models of asthma or chronic obstructive
pulmonary disease. (a) Structure of the HDAC1/2/3 selective inhibitor entinostat. (b) Structure of the
HDAC6 selective inhibitor tubastatin A. (c) Structure of the HDAC8 selective inhibitor PCI-34051. (d)
Structure of the non-selective HDAC inhibitor trichostatin A.
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6. Design of Selective HDACi Targeting the Catalytic Site
The clear beneficial effects of selective HDACi in the described models of asthma and COPD
advocate the further development of selective inhibitors. An overview of ongoing medicinal chemistry
efforts in this area is provided in this section. The general pharmacophore of HDACi comprises a cap
group that interacts with the rim of the enzyme’s cavity that is connected via a hydrophobic spacer to
a zinc binding group (ZBG). The largest group of HDACi, including three of the four FDA-aproved
drugs, contain a hydroxamic acid as a bidentate zinc chelator. The hydroxamic acid moiety can
target HDACs from various classes (like TSA, Figure 2D), but has also been used to engineer the
HDAC6 selective inhibitor Tubastatin A (Figure 2B) and the HDAC8 selective inhibitor PCI-34051
(Figure 2C). The selectivity difference between these hydroxamic acid HDACi is poorly understood
but is under active investigation [99]. Additionally, compounds with an o-aminoanilide ZBG (like
entinostat, Figure 2A) have been developed, and these mainly target HDAC1/2 and 3. The reason
for this specificity between the ZBGs is that HDAC1/2 and 3 have an additional 14 Å-wide cavity in
the active site, called the foot pocket [100]. HDAC8 and the other HDACs lack a foot pocket, thus
conferring insensitivity towards these bigger ZBGs. The foot pocket is thought to accommodate the
acetate byproduct that is generated during the hydrolysis of the acetyl group. Furthermore, the foot
pocket is hypothesized to connect to an acetate release tunnel, whose exit is controlled by gate-keeping
aromatic amino acids that only transiently open to allow acetate to escape [101]. It is, therefore,
attractive to consider HDACs as dynamic scissors, efficiently cutting acetyl groups off lysine residues.
More importantly, the acetate cavity has enabled the design of selective inhibitors targeting either
HDAC1 and HDAC2 or HDAC3 through the modification of the o-aminoanilide ZBG.
Structure–Activity Relationship of Reported o-Aminoanilides for Selective Inhibition of HDAC1/2/3
Crystal structures of an o-aminoanilide in complex with an HDAC show that the amino and
anilide groups together chelate the zinc ion through an unusual seven-membered ring (see Figure 3,
middle). Introducing a group on the amine, or modifying the anilide accordingly leads to a loss
of potency [102,103]. However, exchanging the amino group for a hydroxyl does not make a
difference [102,104], indicating that both are able to interact with the zinc ion. Figure 3 shows the
effects of substitutions on the anilide ring on the HDAC isoenzyme inhibitory selectivity. Substitutions
at position 2, ortho to the amine, or position 3, meta to the amine, give rise to interesting selectivity
profiles. Compounds bearing a fluorine atom in position 3 show an outstanding selectivity for HDAC3
inhibition, like compound 1 and 2 [105]. Replacing fluorine with a chlorine leads to a decrease in
potency similar to replacement with the electron-donating methyl and methoxy groups [102,106].
Collectively, strong but small electron-withdrawing groups in position 3 will lead to potent and selective
inhibition of HDAC3, while either larger or electron-donating groups will decrease it. Contrarily,
compounds with a fluorine atom or methyl group in position 2 completely lose their ability to inhibit
HDACs [102,107]. The same is true for modifications in position 5, meta to the amine, but on the side
of the anilide; a fluorine in that position leads to a significant loss in potency [107]. Substituents in
position 2 or 5 probably sterically hinder the amino and anilide groups, thereby preventing proper
coordination towards the zinc ion.
Concerning position 4, para to the amine, compound 3 with a fluorine atom in that position is also
reported to selectively inhibit HDAC3, with a respective 15- and 19-fold higher concentration needed
for the inhibition of HDAC1 and 2 [107]. An even better selectivity profile is obtained by combining a
fluorine in position 2 with one in position 4, as illustrated in compound 4 [107]. In comparison, the
unsubstituted analogue (compound 5) has IC50 values of 2.4 µM, 3.3 µM, and 2.8 µM for HDAC1/2/3,
respectively [104]. Interestingly, aromatic substituents in position 4 lead to selective inhibition of
HDAC1 and HDAC2 over HDAC3 [104,108,109]. For example, compound 6, in which a phenyl ring
is introduced in position 4, has corresponding IC50 values of 0.06 µM, 0.78 µM and 11 µM. Other
investigations confirmed that aromatic groups in the 4 position, such as 2-thienyl (compound 7) [104],
2-furyl (compound 8) [108], 3-furyl (compound 9) [108] and 4-pyrimidinyl (compound 10) [103], result
Epigenomes 2019, 3, 19 9 of 25
in preferential binding to HDAC1 and 2. Insertion of an oxygen-, carbonyl-, or ethyl-linker between
the aromatic substituents and the o-aminoanilide ring leads to a decrease in potency (not shown in
Figure 3) [104]. Some experiments were conducted with o-aminoanilide derivatives with a carboxylic
acid or a carboxamido group in the 4 position, but this reduced their ability to inhibit HDAC1 [104].
Potential inhibition of other HDACs was in this case unfortunately not investigated. Other changes
in position 4 are based on the further modification of the aromatic rings in position 4. Most of these
substituents (e.g., 4-chlorophenyl, 4-trifluoromethylphenyl) did not improve selectivity. Compound
11, however, having a 4-fluorophenyl in position 4, is promisingly potent, with an IC50 of 0.029 µM
for HDAC1. A 2-fold higher concentration is needed for inhibition of HDAC2, and a 38-fold higher
concentration for HDAC3 inhibition [103]. Interestingly, 3-fluorophenyl substituents (compound 12)
decrease potency, with a 333-fold increase in the IC50 for HDAC1, 198-fold for HDAC2, and even no
inhibition of HDAC3 at the measured concentrations [103]. From the findings above it becomes clear
that small differences in the substitution pattern of o-aminoanilides result in substantial differences in
potency and selectivity. In conclusion, a fluorine in position 3 confers selectivity towards HDAC3,
while aromatic substitutions in position 4 only fit in the foot pocket of HDAC1 and HDAC2 and thereby
confer selectivity towards HDAC1 and HDAC2. Selectivity between HDAC1 and HDAC2 has so far
not been described for o-aminoanilide HDACi.
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Figure 3. Structure–activity relationship of reported o-a inoanilides. In brief, fluor atoms in position 3
or 4 give rise to HDAC3 selective inhibitors (compounds 1–4, orange circles) and aromatic groups in
position 4 (compounds 6–12, purple circles) push selectivity towards HDAC1 and 2. The unsubstituted
o-aminoanilide (compou 5, white circle) inhibits HDAC1,2 and 3 with qual potency. Compounds
with substitutio s at ither 2 or 5 (not shown) are unable to inhibit HDACs at relevant concentrations.
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7. Targeting HDAC Complexes
7.1. Class I HDAC Complexes
The next step in the design of selective HDACi would be to go from structure-activity relationships
on single enzymes to structure-activity relationships on HDACs as part of a broad set of multi-protein
complexes with diverse functions. HDAC1 and 2 form the catalytic core of the complexes Sin3
(switch-independent 3), NuRD (nucleosome remodeling and deacetylase), CoREST (co-repressor of
REST), MIER (mesoderm induction early response), RERE (arginine-glutamic acid dipeptide repeats),
and MiDAC (mitotic deacetylase). The structures of HDAC1 and HDAC2 are very similar, and as
such, are recruited interchangeably towards the same complexes [110]. Additionally, HDAC1 and
HDAC2 can form hetero- and homodimers and dimerization enhances their activity [111]. HDAC3 gets
recruited exclusively towards the SMRT/NCoR (nuclear receptor co-repressor) complex. Furthermore,
HDAC8 does not form a complex with other proteins [112]. Complex formation of HDAC1/2/3 is
needed for maximum deacetylase activity and provides directionality towards specific places of the
genome. Additionally, HDAC complex formation influences the binding preference of HDACi. In
the case of o-aminoanilide HDACi, one study showed that these inhibitors preferentially bind to the
HDAC3/NCoR complex rather than the NuRD, CoREST or MiDAC HDAC complexes [113]. The
Sin3/HDAC1/2 complex was shown not be targeted by these HDACi at all, which is largely due to
thermodynamic rather than kinetic reasons [114]. This interesting finding prompts us to review HDAC
protein complexes important in inflammation, because this is relevant for the development of inhibitors.
Also, novel examples will be given regarding drugs developed to specifically target these complexes
since the most recent review [115].
7.2. The Sin3 Complex
7.2.1. Structure of Sin3
Sin3 acts as a scaffold protein for HDAC1 and HDAC2 and other proteins that guide HDACs
to their target [116]. Humans harbor two isoforms of Sin3—Sin3A and Sin3B—that are expressed
ubiquitously throughout the body. The scaffolds are considered to be master gene regulators that are
highly conserved throughout the phylogenetic tree of life. They show about 57% structural homology
and are found to bind both the same and divergent transcription altering proteins [116,117]. Elucidating
the complete structural properties and targets of the Sin3 protein complex is currently a topic of active
research [118].
7.2.2. Roles of Sin3
Classically, Sin3 is the prototypical DNA repressor complex since it directs HDACs towards the
chromatin, specifically towards histones H3 and H4. Their subsequent deacetylation increases the
interaction of the chromatin with the histones and yields Sin3 mediated gene repression. However, in
Sin3 knockout studies in fruit flies, yeasts and mice, both transcriptional up- and down-regulation
have been observed [119–122]. As a consequence, the Sin3 complex has been defined as a co-repressor,
co-activator and general transcription factor in recent literature [123]. How Sin3 increases gene
transcription is currently unknown. It is anticipated to be important in regulation of crucial cellular
functions. As an example, a study performed in fruit flies showed that Sin3 deficient cells have a
delayed G2 phase. These cells also exhibit increased expression of genes related to energy metabolism
and displayed increased mitochondrial mass [121]. Additionally, Sin3 is important in repressing cell
division [124]. This is exemplified by studies linking Sin3 deficiency to an increase in cell invasion and
tumorigenesis [125]. More examples of the effects on cellular proliferation, apoptosis, differentiation
and cell cycle regulation are reviewed elsewhere [118,122]. Taken together, these studies suggest that
the Sin3 complex is important in the regulation of genes important in cell maturation.
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7.2.3. Examples of Sin3 Targeting
Targeting the Sin3 complex or subsets of the Sin3 complex in cancer might be beneficial because
of its importance in cellular development [126]. Indeed, inhibition of Sin3 complex formation in
breast cancer models shows potential [127]. The researchers used the antiparasitic drug ivermectin
(Figure 4A), which blocks the formation of Sin3 by occupying a protein–protein binding site [127].
Mutations were made in proteins of the Sin3 complex to identify important residues for protein–protein
interaction. They showed that preventing protein–protein binding with ivermectin is indeed a way to
impair complex formation. Additionally, the efficacy of ivermectin for the treatment of asthma has
been tested in a mouse model. Ivermectin significantly diminished the production of the cytokines IL-4,
IL-5 and IL-13 and reduced the recruitment of neutrophils and eosinophils [128]. However, ivermectin
has many different modes of action, including through interaction with ligand-gated channels [129],
and it is therefore unclear to what extent disruption of the Sin3 complex contributes to the observed
anti-inflammatory effects.
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7.3. The NuRD Complex.
7.3.1. Structure of the NuRD Complex
The core of the NuRD complex consists of a dimer of the histone binding proteins MTA1/2/3,
four copies of RBBP4/7 and two copies of either HDAC1 or HDAC2 or a mix of HDAC1 and HDAC2.
Additionally, two copies of the methyl binding domain proteins MBD2/3 can join in to mediate the
association with MTA1/2/3 and modify deacetylase activity [130]. The nuclear zinc-finger transcriptional
repressor p66-α (GATAD2A) and p66-β (GATAD2B) also directly interact with MBD proteins [131].
Finally, Mi-2α/β, also known as CHD3/4, which is a chromodomain-helicase-DNA-binding protein
that uses ATP to modify the chromatin structure is also able to bind to the complex [132]. Recruitment
of the two copies of HDAC1/2 towards the complex is mediated by the dimeric ELM2-SANT
domain of MTA1/2/3, accompanied by the four equivalents of RBBP4/7 towards the C terminus
of MTA1/2/3 [115,133–135].
Epigenomes 2019, 3, 19 12 of 25
7.3.2. Roles of NuRD
Overall, NuRD is regarded as an important mediator during the developmental stages of life,
playing important roles in cell cycle progression, DNA repair and chromatin remodeling [136]. Hence,
targeting this complex could be beneficial in regenerative medicine or cancer. For example, it has been
shown that Mi2-β has intrinsic activities on its own, as it associates with a CD4 gene transcription
enhancer and the HAT p300 to increase CD4 gene expression needed in T-cell development [137].
Additionally, different MTA1/2/3 subtypes are found in distinct complexes where they have different
functions [138]. For example, MTA1, which is upregulated in a variety of tumors [139], has also been
shown to be a regulator of inflammatory homeostasis [140]. Researchers found that MTA1 transcription
was upregulated in LPS induced cells through an NF-κB controlled mechanism. They also found
fewer MTA1:HDAC2 repressor complexes near LPS inducible genes such as IL-1β, TNF-α and MIP2.
Furthermore, expression levels of IL-1β and TNF-α in macrophages from LPS induced MTA1 knockout
mice were 6.7- and 3.72-fold higher than in wild-type. This is indicative of the double role of MTA1,
repression of inflammatory genes under basal conditions but an inflammatory mediator upon NF-κB
activation [140]. Taken together, these studies suggest an enhancing role for MTA1 in inflammation
and a repressing role for MTA1:HDAC2 of inflammatory genes via deacetylation or occupation of
the promoters. Therefore, MTA1 is a potential drug target to suppress inflammation in inflammatory
disease [141]. More research regarding this interaction is needed for a precise determination of
the mechanisms.
7.3.3. Targeting NuRD
Resveratrol (Figure 4B), a dietary supplement found in grapes, decreases expression of MTA1
in prostate cancer cells [142]. This in turn decreases the amount of MTA1:HDAC1 complexes. How
resveratrol decreases expression is unknown. Additionally, MTA1 inhibition by pterostilbene, a
compound that has a similar structure and function to resveratrol, in combination with a HDACi has
shown to be effective in a prostate cancer mouse model [143]. Effectivity in models of inflammation
remains to be investigated. Selective targeting of the many different NuRD complexes is difficult,
since there are several possible combinations between the subunits and structural information of each
subunit is incomplete.
7.4. The CoREST Complex
7.4.1. Structure and Roles of the CoREST Complex
The structural information on the CoREST complex is the most complete, probably because
CoREST is one of the smallest complexes known to form complexes with HDACs. The complex
consists of one HDAC1 and HDAC2, one CoREST1/2/3 scaffold protein and one lysine-specific histone
demethylase 1(LSD1) [144,145]. The CoREST scaffold subtypes each have different effects on the other
proteins in the complex [146]. It is anticipated that the CoREST protein binds to HDACs using a
ELM2-SANT domain and does not form dimers [147]. The general consensus is that the CoREST
complexes are important in regulation of neuronal genes [148]. Furthermore, CoREST is shown to
be important in inducing and maintaining specific neuronal subtypes [149]. This could conceivably
be used to develop compounds to combat neurodegenerative diseases such as Alzheimer’s and
Parkinson’s diseases.
7.4.2. Targeting CoREST
Knowing that HDACi have varying inhibition kinetics towards HDACs depending on which
complex they are incorporated in, researchers set out to identify HDACi with specificity towards
CoREST for use in neurological diseases. They identified compound Rodin-A (Figure 4C), which
showed a decrease in hematological toxicity compared with a non-selective HDACi. Rodin-A has a
139-fold selectivity towards CoREST compared with a 123-fold selectivity over Sin3 and NuRD and
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an 88-fold selectivity over NCoR [150]. An excellent example in which fundamental knowledge of
protein interactions and structures aids rational drug design is given by the development of corin
(Figure 4D), a synthetic dual inhibitor directed towards the two catalytically active sites of enzymes
in the CoREST complex. The researchers combined the HDACi entinostat (Figure 2A) and an LSD1
inhibitor, a tranylcypromine analog, in a bi-valent molecule with a short linker that showed increased
selectivity towards CoREST and prolonged inhibition kinetics due to irreversible binding of the LSD1
inhibitor [151]. This confirms the notion that molecules targeted towards multiple proteins in one
complex increase selectivity towards that specific complex.
7.5. The SMRT/NCoR Complex
7.5.1. Structure of SMRT/NCoR
SMRT and NCoR are co-repressor proteins with great homology that interact with nuclear
hormone receptors, such as retinoid and thyroid hormone receptors, and with several other proteins
to repress transcription [152,153]. SMRT forms complexes with HDAC3 and HDAC4, but only
HDAC3 gets activated through a deacetylase-activating domain (DAD) that includes one of two SANT
motifs located on the SMRT protein [154]. NCoR possesses a similar DAD domain determined by
homology. In addition to HDAC3, SMRT and NCoR also form complexes with GPS2 and TBL1 that
both interact with a conserved core region located on the SMRT/NCoR proteins named repression
domain-1 (RD1) [152,155–157]. Furthermore, SMRT and NCoR recruit other HDACs such as HDAC5,
HDAC7 and HDAC9 [158]. The exact role of these class IIa HDACs in this complex has not been
determined yet, although HDAC3 is likely to be the sole enzymatic subunit responsible for deacetylase
activity, since the other HDACs do not possess catalytic activity of their own [159,160]. Importantly,
inhibition of HDAC3 should therefore fully abolish the deacetylase function of the SMRT/NCoR
complex. Also, interaction with the Sin3 complex, and thus HDAC1 and HDAC2, has been described.
However, it is anticipated that this interaction is not a core characteristic of SMRT/NCoR [161].
7.5.2. Roles of SMRT/NCoR
The role of SMRT/NCoR is well defined. Characterization of NCoR-deficient mice showed
its role in central nervous system development and in the development of T-lymphocytes and
erythrocytes [162]. SMRT on the other hand fulfills a critical role in forebrain development and in the
determination of neuronal stem cell fate [163]. Additionally, a fundamental role in the development
of the heart is described [164]. In addition to its roles in development, SMRT/NCoR is involved in
the regulation of the alternative activation pathway of macrophages. While classically LPS-activated
macrophages are polarized to contribute to the progression of inflammation, alternatively IL-4-activated
macrophages are polarized to secrete anti-inflammatory mediators. The HDAC3/SMRT/NCoR complex
has been shown to suppress the IL-4-activated alternative pathway and is thereby believed to act as a
brake for alternative activation [165]. Loss of HDAC3 removes this brake and thereby promotes the
IL-4-induced alternatively activated phenotype [166]. Alternatively, the HDAC3/NCoR complex is
proposed to suppress the transcription of the pro-inflammatory iNOS gene in classically activated
macrophages [167]. In LPS-induced macrophages, this complex is degraded through the ubiquitin
conjugating/19S proteasome system recruited by TBL1 [168], leading to upregulation of the iNOS
expression. Conversely, HDAC3 is also reported to be required for the activation of inflammatory genes
in classically activated macrophages, as evidenced from a HDAC3 knockout study [72]. This study,
however, did not knock-out NCoR or SMRT, and the effect of the entire complex on inflammatory gene
expression thereby remains to be investigated. Altogether, HDAC3/NCoR represses the expression
of both pro- and anti-inflammatory genes in macrophages. In classically activated macrophages, the
repression of pro-inflammatory genes is abolished by destruction of the complex. In alternatively
activated macrophages the complex represses anti-inflammatory genes. We therefore predict that
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inhibition of HDAC3 is most beneficial in boosting the polarization of macrophages to become
alternatively activated upon IL-4 stimulation.
7.5.3. Targeting SMRT/NCoR
The described repression of pro-inflammatory genes by HDAC3/SMRT/NCoR in LPS-stimulated
macrophages suggests that inhibition of HDAC3 might aid in lifting the repression and cause an
increase in the expression of pro-inflammatory genes. However, several studies report that treatment
of LPS-activated macrophages with the HDAC3 selective inhibitor RGFP966 does not have a significant
impact on pro-inflammatory gene expression, except at relatively high concentrations, at which
RGFP966 also inhibits HDAC1 and HDAC2 [81]. This could be a consequence of the described removal
of the HDAC3/SMRT/NCoR complex from the chromatin upon LPS stimulation, thereby rendering
inhibition useless. Yet, in the same study, siRNA mediated knock-down of HDAC3 yields a robust
attenuation of LPS-induced inflammatory gene expression. It is, however, possible that without
HDAC3, the rest of the SMRT/NCoR complex is not removed, perhaps by a failure to recruit TBL1 and
the proteasomal degradation system. The remaining SMRT/NCoR complex could retain its repressing
properties by mere occupation of inflammatory promotor sequences [169], while absence of unbound
HDAC3 attenuates the inflammatory response. Alternatively, in IL-4-stimulated macrophages RGFP966
clearly enhances the expression of anti-inflammatory genes and promotes the alternative activation of
macrophages. Future investigations should investigate whether the effects of either HDAC3 inhibition
or knock-out in macrophages translates to a beneficial effect on inflammation in asthma or COPD.
7.6. The Role of Inositol Phosphates in HDAC Complex Formation
HDAC1/2/3 have an inositol phosphate (InsP) binding site and binding of InsP enhances the
deacetylase activity of HDAC complexes. In a study done in embryonic stem cells, mutation of
the inositol tetraphosphate binding site of HDAC1 and HDAC2 resulted in reduced HDAC activity
in vivo [170]. A different study done in yeast also suggested a critical role for this allosteric site in
regulation of HDAC activity [171]. The InsP binding site is a positively charged binding pocket that
facilitates the binding of the multiple negatively charged phosphate groups of InsP. It is located close
to the active site and allows for binding with co-repressor proteins. Co-repressor proteins and HDAC
enzymes are simultaneously in contact with InsP and InsP can thus be viewed as a form of molecular
glue, bonding the complex together [133,172,173]. A modeling study done on the crystal structure of
HDAC3 in complex with SMRT/NCoR and InsP suggests that binding of InsP and DAD stabilize the
backbone of HDAC3 [174]. Also, the HDAC activity can increase or decrease depending on the type of
InsP that binds. Allosteric inhibition of HDAC1/2/3 by InsP mimics may be possible, but the generic
role of InsP in many different signaling pathways would greatly complicate such an approach.
8. Future Perspectives
We have summarized the beneficial effects of both selective and more general HDACi on the
inflammatory mechanisms of both asthma and COPD that require further investigation. One area of
further research is to combine the features of isoform selective inhibitors to yield unique selectivity
profiles that could potentially further improve their positive benefit-risk ratios. A uniquely selective
HDAC3/6 inhibitor, for instance, would combine the attenuation of cytokine expression by inhibition
of HDAC3 with the reduction of immune cell motility by inhibition of HDAC6, without eliciting the
pleiotropic effects of HDAC1/2 inhibition. For instance, an HDAC3/6 inhibitor of unknown structure
reproduced the anti-inflammatory effects of reduced expression of HDAC3 in an in vitro model of
rheumatoid arthritis [175]. Other unique combinations left to explore are HDAC1/2/6, HDAC1/2/8 and
HDAC3/8 inhibitors. A dual action HDAC6/8 inhibitor already exists, but has not been tested yet in
inflammatory models [176].
Furthermore, the finding that HDACs exist in specific complexes has been used to design inhibitors
for specific complexes, like the dual-warhead LSD-1/HDAC1/2/3 inhibitor corin (Figure 4D) directed
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to CoREST. The availability of structural information of the specific HDAC complexes will aid the
discovery of comparable examples. Besides, further modification of o-aminoanilide-type HDACi might
similarly yield complex-selective inhibitors as exemplified by Rodin-A (Figure 4B).
Lastly, due to the important structural role of HDACs in protein complexes, prevention of HDAC
complex formation by protein–protein interaction inhibitors is an interesting option. A more novel
but related approach is to target enzymes for degradation using the proteolysis targeting chimera
(PROTAC) technique [177]. In this respect, PROTAC molecules for the selective degradation of HDAC6
(Figure 5) have recently been developed [178,179]. The compounds consist of an HDAC inhibitor
directed to the HDAC catalytic site and the E3 targeting ligand thalidomide, to bind to an E3 ubiquitin
ligase complex, coupled together with a linker [180–182]. It is interesting to note that while compound
9c (Figure 5A) contains the non-selective inhibitor crebinostat [183], it is reported to selectively degrade
HDAC6. This may be the result of the formation of a stable ternary complex between the E3 ligase
and HDAC6 and not with the other HDACs [182], but further research is needed to confirm this.
Compound Np8 (Figure 5B) contains the HDAC6 selective inhibitor nexturastat A [184]. Finally, small
molecules that selectively degrade HDAC1/2 or 3 have not yet been developed, and this is therefore
an interesting area for further research. PROTACs for specific complexes may even be developed by
adding ubiquitin ligase functionalities to the described complex-specific inhibitors. With these new
strategies, the validation of HDACs as targets for improved therapies for asthma and COPD enters an
exciting new era.
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